GI
MLTX icon

GAMMA Investing’s MoonLake Immunotherapeutics MLTX Stock Holding History

GAMMA Investing’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273 Buy
+14
New +$254 ﹤0.01% 4058
2025
Q4 		– Sell
-6
Closed -$43 – 4116
2025
Q3 		$43 Buy
+6
New +$313 ﹤0.01% 3834

Other funds holding MLTX

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing's MLTX Position: Q2 2026 in Review

GAMMA Investing opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 14 shares worth $273. The stake represents ﹤0.01% of the portfolio and ranks #4058 among its holdings. This is a return to the name: GAMMA Investing previously reported a position in MLTX as recently as Q3 2025.

GAMMA Investing first reported a position in MLTX in Q3 2025 and has held it in 2 quarters since. 14 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • GAMMA Investing held 14 shares of MoonLake Immunotherapeutics worth $273 as of Q2 2026.
  • MoonLake Immunotherapeutics was a new GAMMA Investing position in Q2 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #4058 holding.
  • GAMMA Investing first reported a position in MoonLake Immunotherapeutics in Q3 2025 and has held it in 2 quarters since.
  • 14 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.